Health-Related Quality of Life with Sacituzumab Govitecan in HR+/HER2− Metastatic Breast Cancer in the Phase III TROPiCS-02 Trial

    April 2024 in “ The Oncologist ”
    Hope S. Rugo, Peter Schmid, Sara M. Tolaney, Florence Dalenc, Frederik Marmé, Ling Shi, Wendy Verret, Anuj Shah, Mahdi Gharaibeh, Aditya Bardia, Javier Cortés
    TLDR Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
    The phase III TROPiCS-02 trial evaluated the health-related quality of life (HRQoL) in patients with HR+/HER2− metastatic breast cancer treated with sacituzumab govitecan (SG) compared to treatment of physician’s choice (TPC) chemotherapy. The study found that SG provided superior clinical outcomes and HRQoL benefits in most symptoms and functioning, such as physical functioning and dyspnea, compared to TPC. However, SG was associated with worse outcomes for diarrhea. Time to first clinically meaningful worsening or death was longer for SG in several quality of life measures, although diarrhea was better managed with TPC. The findings support SG as a favorable treatment option for patients with pretreated HR+/HER2− mBC.
    Discuss this study in the Community →